4
Changes in Ownership
MoonLake Immunotherapeutics Filed Acc 0001213900-26-070259
Chief Financial Officer sold 17,876 shares at an average $19.67 ($351,576)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Bodenstedt Matthias Chief Financial Officer | 2026-06-17 | Sale 10b5-1 | −15,082 | $19.68 | $296,814 | 1,157,349 | D |
| Bodenstedt Matthias Chief Financial Officer | 2026-06-18 | Sale 10b5-1 | −2,794 | $19.60 | $54,762 | 1,154,555 | D |
| Open-market sales · 17,876 sh · avg $19.67 · $351,576 | |||||||
Loading xslF345X06/ownership.xml…